CONNECT WITH US
HealthTech

HealthTech

Lilly interested in ibogaine investments, its neuro leader says

Endpoints News logo

Published on

Add as a preferred source on Google
Lilly interested in ibogaine investments, its neuro leader says

Lilly Neuroscience president Carole Ho (L) with Psychedelic Alpha founder Josh Hardman at the Psychedelic Healthcare Forum on Oct. 15, 2026 (Kyle LaHucik for Endpoints News)

Lil­ly wants to study and im­prove the psy­che­del­ic ibo­gaine, its neu­ro leader says

Eli Lil­ly is in­ter­est­ed in R&D ef­forts to “im­prove the pro­file of ibo­gaine,” the phar­ma gi­ant’s neu­ro­science pres­i­dent said at a psy­che­delics con­fer­ence Thurs­day.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.